CONNOR MCVEY: Open Payments
NPI 1215415633 · LONGWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,904 in 78 payments from 15 companies in 2025. Trend: 2023 $950 · 2024 $1,579 · 2025 $1,904
Food & beverage: $1,904
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 10 | $306 |
| Otsuka America Pharmaceutical, Inc. | 11 | $279 |
| Neurocrine BioSciences, Inc. | 9 | $259 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $208 |
| ABBVIE INC. | 12 | $207 |
| E.R. Squibb & Sons, L.L.C. | 7 | $131 |
| Janssen Pharmaceuticals, Inc | 5 | $114 |
| Alkermes, Inc. | 4 | $95 |
| Lundbeck LLC | 3 | $74 |
| Bausch Health US, LLC | 3 | $54 |
Products named: INGREZZA, REXULTI, CAPLYTA, VRAYLAR, FANAPT, COBENFY, HETLIOZ, ABILIFY ASIMTUFII.
Industry payments across FL — which companies pay providers there.
